TG Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 6/6

TG Therapeutics kazanç ve gelirin sırasıyla yıllık 45.3% ve 30.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 44.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 38.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

45.3%

Kazanç büyüme oranı

44.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	26.8%
Gelir büyüme oranı	30.1%
Gelecekteki özkaynak getirisi	38.4%
Analist kapsamı	Good
Son güncelleme	11 Dec 2024

Gelecekteki son büyüme güncellemeleri

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09

Recent updates

Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking

Nov 07

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

Nov 05

TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Sep 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

May 29

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 04

TG Therapeutics: Less Room For Doubt About Briumvi

May 03

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

May 03

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:TGTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	1,103	466	418	N/A	3
12/31/2026	746	273	271	153	5
12/31/2025	541	157	127	112	8
12/31/2024	330	23	-32	-21	8
9/30/2024	265	-14	-28	-28	N/A
6/30/2024	347	96	68	68	N/A
3/31/2024	289	41	20	20	N/A
12/31/2023	234	13	-31	-31	N/A
9/30/2023	190	-26	-42	-42	N/A
6/30/2023	24	-176	-160	-160	N/A
3/31/2023	9	-169	-167	-167	N/A
12/31/2022	3	-198	-176	-176	N/A
9/30/2022	5	-239	-239	-239	N/A
6/30/2022	7	-288	-272	-272	N/A
3/31/2022	8	-326	-283	-283	N/A
12/31/2021	7	-348	-296	-296	N/A
9/30/2021	4	-343	-261	-261	N/A
6/30/2021	2	-345	-251	-250	N/A
3/31/2021	1	-319	-234	-234	N/A
12/31/2020	0	-279	-215	-215	N/A
9/30/2020	0	-231	-193	-193	N/A
6/30/2020	0	-206	-170	-170	N/A
3/31/2020	0	-189	-162	-162	N/A
12/31/2019	0	-173	-133	-133	N/A
9/30/2019	0	-187	-136	-136	N/A
6/30/2019	0	-159	-136	-136	N/A
3/31/2019	0	-167	-134	-134	N/A
12/31/2018	0	-173	-129	-129	N/A
9/30/2018	0	-150	-117	-117	N/A
6/30/2018	0	-148	N/A	-107	N/A
3/31/2018	0	-132	N/A	-100	N/A
12/31/2017	0	-118	N/A	-94	N/A
9/30/2017	0	-111	N/A	-89	N/A
6/30/2017	0	-105	N/A	-81	N/A
3/31/2017	0	-92	N/A	-67	N/A
12/31/2016	0	-78	N/A	-62	N/A
9/30/2016	0	-72	N/A	-57	N/A
6/30/2016	0	-61	N/A	-53	N/A
3/31/2016	0	-62	N/A	-52	N/A
12/31/2015	0	-63	N/A	-45	N/A
9/30/2015	0	-64	N/A	-47	N/A
6/30/2015	0	-68	N/A	-44	N/A
3/31/2015	0	-63	N/A	-36	N/A
12/31/2014	0	-56	N/A	-35	N/A
9/30/2014	0	-43	N/A	-25	N/A
6/30/2014	0	-30	N/A	-18	N/A
3/31/2014	0	-24	N/A	-17	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TGTX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: TGTX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: TGTX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: TGTX şirketinin gelirinin (yıllık 30.1% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: TGTX şirketinin gelirinin (yıllık 30.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TGTX 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 38.4 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/02 05:35
Gün Sonu Hisse Fiyatı	2025/01/02 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

TG Therapeutics, Inc. 20 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alec Stranahan	BofA Global Research
Jonathan Aschoff	Brean Capital
Mayank Mamtani	B. Riley Securities, Inc.

TG Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 6/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 9.5% to US$40.75

Price target increased by 7.4% to US$38.67

Price target increased by 8.6% to US$36.67

Price target increased by 8.3% to US$34.25

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates upgraded to US$0.019 loss

Recent updates

Price target increased by 9.5% to US$40.75

Price target increased by 7.4% to US$38.67

Independent Director recently sold US$490k worth of stock

Independent Director notifies of intention to sell stock

Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.34 loss in 2Q 2023)

Price target increased by 8.6% to US$36.67

Investor sentiment improves as stock rises 15%

TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Price target increased by 8.3% to US$34.25

TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Investor sentiment improves as stock rises 16%

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Receives U.S. Food and Drug Administration Clearance for Its Investigational New Drug (IND) Application

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

TG Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates upgraded to US$0.019 loss

Independent Director recently sold US$433k worth of stock

Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission

CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics

Hold TG Therapeutics For Intriguing Outcomes

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Investor sentiment improves as stock rises 26%

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

TG Therapeutics: Less Room For Doubt About Briumvi

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Price target increased by 15% to US$34.14

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

TG Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Consensus EPS estimates fall by 42%, revenue upgraded

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Lead Independent Director recently sold US$351k worth of stock

Consensus EPS estimates fall by 24%

TG Therapeutics: Briumvi Growth Story Appears Intact

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$32.57

Price target increased by 10% to US$32.43

TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 9.2% to US$29.07

Forecast breakeven date pushed back to 2024

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Price target increased by 11% to US$29.44

CFO, Corporate Secretary & Treasurer recently sold US$809k worth of stock

CFO, Corporate Secretary & Treasurer notifies of intention to sell stock

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Price target decreased by 9.1% to US$25.06

Consensus EPS estimates upgraded to US$0.57 loss, revenue downgraded

Forecast breakeven date pushed back to 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Consensus EPS estimates fall by 24%

Chairman recently bought US$1.0m worth of stock

New major risk - Financial position

No longer forecast to breakeven

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Price target decreased by 8.4% to US$29.06

TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Consensus revenue estimates increase by 11%

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Independent Director recently sold US$815k worth of stock

Forecast breakeven date moved forward to 2024